Carregant...
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
INTRODUCTION: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival. However, the drug has little effect on the underlying bone marrow fibrosis o...
Guardat en:
| Publicat a: | Expert Opin Orphan Drugs |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577425/ https://ncbi.nlm.nih.gov/pubmed/33094033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2019.1664900 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|